See every side of every news story
Published loading...Updated

FDA Suspends New Application Fees - BusinessWorld Online

  • Following an increase in licensing fees for drug distributors in December 2024, the FDA announced a temporary halt on implementing recently introduced charges related to registering and evaluating medical products, impacting approximately 3,000 outstanding applications in the Philippines.
  • The suspension followed industry concerns about fee increases without sufficient consultation and calls for legislation to support domestic medicine production and streamline regulatory processes.
  • FDA Director Paolo S. Teston briefed the House, highlighting that slow permit processing raises medicine prices and promising proposed solutions to clear application backlogs.
  • Separately, the FDA mandated Pfizer and Moderna update COVID-19 vaccine labels to warn of myocarditis risks in males aged 16-25, citing a Lancet study showing 60% with heart injury markers five months after diagnosis.
  • This action ended a 13-month delay, raising transparency and long-term safety questions, especially for young males, and prompting the FDA to pledge stronger monitoring amid calls for public candor.
Insights by Ground AI
Does this summary seem wrong?

13 Articles

All
Left
1
Center
1
Right
3
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Right
60% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

LifeSiteNews broke the news in on Saturday, May 24, 2025.
Sources are mostly out of (0)